相似文献
1
A new roadmap for drug development for Alzheimer's disease.
Nat Rev Drug Discov. 2014 Feb;13(2):156. doi: 10.1038/nrd3842-c2. Epub 2013 Dec 20.
2
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
Nat Rev Drug Discov. 2013 Apr;12(4):324. doi: 10.1038/nrd3842-c1. Epub 2013 Mar 15.
3
Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
Alzheimers Dement. 2009 Mar;5(2):147-8. doi: 10.1016/j.jalz.2009.01.007.
4
Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Prevention trials in persons at risk for dominantly inherited Alzheimer's disease: opportunities and challenges.
Alzheimers Dement. 2009 Mar;5(2):166-71. doi: 10.1016/j.jalz.2008.12.002.
5
Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S88-90. doi: 10.1016/j.jalz.2007.11.004. Epub 2007 Dec 21.
6
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke.
Alzheimers Dement. 2009 Mar;5(2):149-53. doi: 10.1016/j.jalz.2009.01.012.
7
Sting of Alzheimer's failures offset by upcoming prevention trials.
Nat Rev Drug Discov. 2012 Sep;11(9):657-60. doi: 10.1038/nrd3842.
8
Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities.
Alzheimers Dement. 2008 May;4(3):164-6. doi: 10.1016/j.jalz.2008.03.007.
9
Genentech's Alzheimer's antibody trial to study disease prevention.
Nat Biotechnol. 2012 Aug;30(8):731-2. doi: 10.1038/nbt0812-731.
10
Prevention therapeutics of dementia.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S122-30. doi: 10.1016/j.jalz.2007.11.005. Epub 2007 Dec 21.
引用本文的文献
1
Development of quantitative detection methods for four Alzheimer's disease specific biomarker panels using electrochemical immunosensors based on enzyme immunoassay.
Anal Sci. 2024 Oct;40(10):1809-1821. doi: 10.1007/s44211-024-00614-7. Epub 2024 Jun 17.
2
GS-SMD server for steered molecular dynamics of peptide substrates in the active site of the γ-secretase complex.
Nucleic Acids Res. 2023 Jul 5;51(W1):W251-W262. doi: 10.1093/nar/gkad409.
3
Compromised autophagy and mitophagy in brain ageing and Alzheimer's diseases.
Aging Brain. 2022 Nov 24;2:100056. doi: 10.1016/j.nbas.2022.100056. eCollection 2022.
4
Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease.
RSC Adv. 2018 Jun 29;8(42):23780-23804. doi: 10.1039/c8ra03620a. eCollection 2018 Jun 27.
5
Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.
Molecules. 2022 Feb 9;27(4):1159. doi: 10.3390/molecules27041159.
6
Phytochemical Analysis and Evaluation of Biological Activity of Seeds Related to Alzheimer's Disease.
Evid Based Complement Alternat Med. 2021 Jul 19;2021:5965061. doi: 10.1155/2021/5965061. eCollection 2021.
7
The Role of Cholesterol in Amyloidogenic Substrate Binding to the γ-Secretase Complex.
Biomolecules. 2021 Jun 24;11(7):935. doi: 10.3390/biom11070935.
8
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Int J Mol Sci. 2021 Apr 23;22(9):4417. doi: 10.3390/ijms22094417.
9
Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors.
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24251-24257. doi: 10.1073/pnas.2006684117. Epub 2020 Sep 14.
10
Subjective Cognitive Decline and Related Cognitive Deficits.
Front Neurol. 2020 May 19;11:247. doi: 10.3389/fneur.2020.00247. eCollection 2020.
本文引用的文献
1
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Alzheimers Dement. 2013 Jul;9(4):438-44. doi: 10.1016/j.jalz.2013.03.007.
2
Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.
Nat Rev Drug Discov. 2013 Apr;12(4):324. doi: 10.1038/nrd3842-c1. Epub 2013 Mar 15.
3
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.
Clin Investig (Lond). 2012 Oct 1;2(10):975-984. doi: 10.4155/cli.12.93.
4
Sting of Alzheimer's failures offset by upcoming prevention trials.
Nat Rev Drug Discov. 2012 Sep;11(9):657-60. doi: 10.1038/nrd3842.
5
Down's syndrome and Alzheimer's disease: towards secondary prevention.
Nat Rev Drug Discov. 2012 Sep;11(9):655-6. doi: 10.1038/nrd3822.
6
β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.
Neurology. 2012 Feb 7;78(6):387-95. doi: 10.1212/WNL.0b013e318245d295. Epub 2012 Feb 1.
7
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.
8
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.
J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):321-9. doi: 10.3233/JAD-2011-0059.
9
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.
Neuropsychologia. 2011 Jul;49(9):2384-90. doi: 10.1016/j.neuropsychologia.2011.04.012. Epub 2011 Apr 16.
10
Lost in translation: neuropsychiatric drug development.
Sci Transl Med. 2010 Dec 8;2(61):61rv6. doi: 10.1126/scitranslmed.3000446.
Zotero 插件